5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE). On Wednesday, several of the company's top executives sat down at the Citi biotech conference to field questions.
Gilead Sciences COO Kevin Young, chief scientific officer Norbert Bischofberger, and CFO Robin Washington participated in what was billed as a "fireside chat." Here are five questions that Gilead's management answered that you'll want to know about.
Image source: Getty Images.
Source: Fool.com
GSK plc ADR Aktie
38,20 €
1,06 %
Die Community bevorzugt leicht GSK plc ADR mit mehr Buy- als Sell-Einschätzungen.
Das niedrigere Kursziel von 35 € im Vergleich zum aktuellen Kurs von 38.2 € für GSK plc ADR führt zu einem negativen Potenzial von -8.38%.
